SCHEMBL2278000

SCHEMBL2278000

O=C(O)Cc1cccc(Oc2ccc(Br)cc2CSc2ccc3ccccc3n2)c1

nearest known ligand 0.45

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PRNP P04156 4/20 0.43
RXFP1 Q9HBX9 2/20 0.43
KDM4E B2RXH2 1/20 0.43
MAPK10 P53779 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
PPARD Q03181 1/20 0.40
PTGDR2 Q9Y5Y4 6/20 0.39
RAB9A P51151 1/20 0.39
MAPT P10636 1/20 0.38
THRA P10827 3/20 0.38
THRB P10828 3/20 0.38
CYSLTR2 Q9NS75 2/20 0.38
CYSLTR1 Q9Y271 2/20 0.38
ALOX5 P09917 1/20 0.38
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2280462 0.89 KMT2A (0.49) PRNPRXFP1KDM4ENPSR1RAB9A
SCHEMBL2279376 0.84 ALDH1A1 (0.46) KDM4ENPSR1PPARDPTGDR2RAB9A
SCHEMBL2282152 0.83 PTGDR2 (0.45) PPARDPTGDR2MAPTTHRATHRB
SCHEMBL2282112 0.81 PTGDR2 (0.43) PPARDPTGDR2THRATHRBCYSLTR2
SCHEMBL2279933 0.80 PPARD (0.39) PPARDPTGDR2THRATHRBCYSLTR2
SCHEMBL2278791 0.80 PTGDR2 (0.46) PPARDPTGDR2THRATHRB
SCHEMBL2275765 0.78 PTGDR2 (0.44) PPARDPTGDR2THRATHRB
SCHEMBL2281413 0.78 CYP1A2 (0.49) PPARDPTGDR2THRATHRBMEN1
SCHEMBL2275762 0.77 PPARD (0.41) PPARDPTGDR2THRATHRB
SCHEMBL2277996 0.76 PTGDR2 (0.40) PPARDPTGDR2CYSLTR2CYSLTR1ALOX5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110190227-A1 Antagonists of Prostaglandin D2 Receptors AMIRA PHARMACEUTICALS, INC. (US) 2011-08-04 US claimed
WO-2010003127-A2 ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS AMIRA PHARMACEUTICALS, INC. (US) 2010-01-07 WO claimed
US-20110190227-A1 Antagonists of Prostaglandin D2 Receptors AMIRA PHARMACEUTICALS, INC. (US) 2011-08-04 US disclosed
US-20110190227-A1 Antagonists of Prostaglandin D2 Receptors AMIRA PHARMACEUTICALS, INC. (US) 2011-08-04 US disclosed
US-20110190227-A1 Antagonists of Prostaglandin D2 Receptors AMIRA PHARMACEUTICALS, INC. (US) 2011-08-04 US disclosed
WO-2010003127-A2 ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS AMIRA PHARMACEUTICALS, INC. (US) 2010-01-07 WO disclosed
WO-2010003127-A2 ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS AMIRA PHARMACEUTICALS, INC. (US) 2010-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190227-A1 Antagonists of Prostaglandin D2 Receptors PTGDR, PTGDR2, PTGER2 PRNP 2091/4885RXFP1 249/4885KDM4E 4832/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.